原健法
推動之可能問題與阻礙
for each isolate
Isolate Characterization
for each drug combination
Checkerboard Method
Initial Evaluation of Drug Combination
Antagonism
Synergy/Additivity
Time-kill Assay
Modeling Effects of Drug Combination on Resistance and Tolerance
Isolate Selection
Isolate Characterization
Drug Selection
(3) Time-kill Assay
Modeling Effects of Drug Combination
In Vitro Combination Testing
(1) Loewe Additivity Based Model
(2) Bliss Independence Based Model
Resistance: (1)(2)(3)
Tolerance: (3)
for each isolate
for each drug combination
Isolate Selection
Isolate Characterization
Drug Selection
Modeling Effects of Drug Combination
Static model for in vitro combination testing (Checkerboard method)
for each isolate
for each drug combination
Dynamic model for in vitro combination testing
(Time-kill assays)
Drug Selection
Isolate Selection
Modeling Effects of Drug Combination
Static model for in vitro combination testing (Checkerboard method)
for each isolate
Dynamic model for in vitro combination testing
(Time-kill assays)
Correlate with Moleclar Mechanism
for each drug
Initial Evaluation of Drug Combination
Antagonism
Synergy/Additivity
Time-kill Assay
Isolate Selection
Isolate Characterization
Drug Selection
(3) Time-kill Assay
Initial Evaluation of Drug Combination
Antagonism
Synergy/Additivity
Time-kill Assay
Modeling Effects of Drug Combination
In Vitro Combination Testing
(1) Loewe Additivity Based Model
(2) Bliss Independence Based Model
Resistance: (1)(2)(3)
Tolerance: (3)
for each isolate
for each drug combination
第四條：「中央衛生福利主管機關應設原住民族健康委員會」
中央行政機關組織基準法：「本法施行後，除本法及各機關組織法規外，不得以作用法或其他法規規定機關之組織。」
Reference:
原住民健康問題不只有醫療 原健法立法衛福部盼多考量 /中央廣播電台
(https://www.rti.org.tw/news/view/id/2083929)
第十二條：「中央主管機關為辦理原住民族健康事務之發展，應設置原住民族健康發展基金」
- 收入來源：二、菸品健康福利捐及公益彩券盈餘之百分之一。
財政紀律法：「各級政府及立法機關制（訂）定或修正法律、法規或自治法規時，不得增訂固定經費額度或比率保障，或將政府既有收入以成立基金方式限定專款專用。」
Reference:
原住民健康問題不只有醫療 原健法立法衛福部盼多考量 /中央廣播電台
(https://www.rti.org.tw/news/view/id/2083929)
第二十四條：「中央衛生福利及科技主管機關機關應每年編列研究經費，比例不得低於年度研究預算之百分之五」
第四條中關於原住民族健康委員會之原住民代表
代表之表性是否充足?
- 中央原民會族群代表即多次受各民族議會、部落頭目抗議表性
Reference:
關鍵評論- 為何《原住民族健康法》草案難以解決原住民族人的「文化安全」問題？ / 朱原慶
(https://phlib.org.tw/最新消息/2020110501/)
第八條第一款之9：「整合原住民族人口及健康相關資料，建置原住民族健康資料庫。」
1. 無法從個別族人實際生活的不同層面，理解疾病生成的社會性因素
2. 代表性不足？
3. 調查工作如何進行？
Reference:
關鍵評論- 為何《原住民族健康法》草案難以解決原住民族人的「文化安全」問題？ / 朱原慶
(https://phlib.org.tw/最新消息/2020110501/)
第十七條第一款：「健康相關業務人員應通過原住民族文化安全認證」
單一研習、訓練課程內容，在短時間內培育文化通才的方法，難以讓照服員完整吸收各族文化內涵
- 文化被再製成淺顯易懂的「單一印象」，最終形成誤解
Reference:
關鍵評論- 為何《原住民族健康法》草案難以解決原住民族人的「文化安全」問題？ / 朱原慶
(https://phlib.org.tw/最新消息/2020110501/)
law of cosines
\(||x_t-x||^2=||x_t-x_{t+1}||^2+||x_{t+1}-x||^2\\ +2\langle x_t-x_{t+1},x_{t+1}-x\rangle\)
optimality condition
\(\langle \nabla f(x_t) + L(x_{t+1}-x_t),x-x_{t+1} \rangle \geq 0\)
proximal inequality
\(\frac{2}{L}\langle \nabla f(x_t),x_{t+1}-x \rangle \leq \\ ||x_t-x||^2-||x_t-x_{t+1}||^2-||x_{t+1}-x||^2\)
smoothness
\(f(x_{t+1})-f(x) \leq \frac{L}{2} (||x_t-x||^2-||x_{t+1}-x||^2)\)
\( f(x_{t+1}) - f(x) \leq \frac{L||x_1-x||^2}{2t}\)
"telescopic sum"
law of cosines
\(||x_t-x||^2=||x_t-x_{t+1}||^2+||x_{t+1}-x||^2\\ +2\langle x_t-x_{t+1},x_{t+1}-x\rangle\)
optimality condition
\(\langle \nabla f(x_t) + L(x_{t+1}-x_t),x-x_{t+1} \rangle \geq 0\)
proximal inequality
\(\frac{2}{L}\langle \nabla f(x_t),x_{t+1}-x \rangle \leq \\ ||x_t-x||^2-||x_t-x_{t+1}||^2-||x_{t+1}-x||^2\)
smoothness
strong convexity
\(f(x_{t+1})-f(x) \leq \frac{L-\mu}{2} ||x_t-x||^2-\frac{L}{2}||x_{t+1}-x||^2\)
\(f(x_{t+1}) - f(x) \leq \frac{\mu||x_1-x||^2}{2((1+\frac{\mu}{L-\mu})^t-1)}\)
"telescopic sum"
three point equality
\(D_h(x,x_t) = D_h(x,x_{t+1}) + D_h(x_{t+1},x_t) + \langle \nabla h(x_{t+1}) - \nabla h(x_t),x-x_{t+1}\rangle\)
optimality condition
\(\langle \nabla f(x_t) + L(\nabla h(x_{t+1})-\nabla h(x_t)),x-x_{t+1} \rangle \geq 0\)
proximal inequality
\(\frac{1}{L}\langle \nabla f(x_t),x_{t+1}-x \rangle \leq \\ D_h(x,x_t)-D_h(x,x_{t+1})-D_h(x_{t+1},x_t)\)
relative
smoothness
\(f(x_{t+1})-f(x) \leq L(D_h(x,x_t)-D_h(x,x_{t+1}))\)
\( f(x_{t+1}) - f(x) \leq \frac{LD_h(x,x_1)^2}{2t}\)
"telescopic sum"
\(E\)
\(E^*\)
\(x_t\)
\(Dh(x_t)\)
\(Dh(x_t)-\eta Df(x_t)\)
\(Dh^{-1}(Dh(x_t)-\eta Df(x_t))\)
\(Dh\)
\(Dh^{-1}\)
\(-\eta Df(x_t)\)
OH
藥廠提出申請
HIRA初步審查
Assessment Committee 評估
NHIS與藥廠
商討藥價
NHIPDC確認
藥物納入健保給付